| 13.3 -0.06 (-0.45%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.23 | 1-year : | 18.96 |
| Resists | First : | 13.89 | Second : | 16.23 |
| Pivot price | 13.36 |
|||
| Supports | First : | 12.84 | Second : | 12.18 |
| MAs | MA(5) : | 13.31 |
MA(20) : | 13.41 |
| MA(100) : | 13.68 |
MA(250) : | 13.99 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.3 |
D(3) : | 40.4 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 15.79 | Low : | 12.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RDY ] has closed above bottom band by 42.5%. Bollinger Bands are 26.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.43 - 13.5 | 13.5 - 13.55 |
| Low: | 13.11 - 13.2 | 13.2 - 13.27 |
| Close: | 13.17 - 13.31 | 13.31 - 13.42 |
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
Sat, 13 Jun 2026
Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif - Business Wire
Wed, 10 Jun 2026
Dr. Reddy’s (NYSE: RDY) schedules June 16–17, 2026 London investor meetings - Stock Titan
Wed, 10 Jun 2026
Dr. Reddy's Laboratories (RDY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Mon, 08 Jun 2026
Dr. Reddy's Laboratories Ltd (RDY) Stock Analysis: Exploring Growth Potential Amidst A 6.95% Upside - DirectorsTalk Interviews
Sun, 07 Jun 2026
RDY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wed, 03 Jun 2026
Dr. Reddy’s (NYSE: RDY) schedules June 2026 investor conferences in Mumbai and Hyderabad - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 833 (M) |
| Shares Float | 600 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 15.1 (%) |
| Shares Short | 20,180 (K) |
| Shares Short P.Month | 13,240 (K) |
| EPS | 0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.79 |
| Profit Margin | 12.7 % |
| Operating Margin | 5.1 % |
| Return on Assets (ttm) | 5.8 % |
| Return on Equity (ttm) | 11.8 % |
| Qtrly Rev. Growth | -11.7 % |
| Gross Profit (p.s.) | 212.9 |
| Sales Per Share | 403.47 |
| EBITDA (p.s.) | 84.68 |
| Qtrly Earnings Growth | -86.2 % |
| Operating Cash Flow | 56,750 (M) |
| Levered Free Cash Flow | 1,740 (M) |
| PE Ratio | 25.09 |
| PEG Ratio | 3.7 |
| Price to Book value | 16.83 |
| Price to Sales | 0.03 |
| Price to Cash Flow | 0.19 |
| Dividend | 0.09 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|